SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 308.37 Billion KRW | 47.96% |
| 2022 | 208.41 Billion KRW | -47.41% |
| 2021 | 396.3 Billion KRW | 1549.57% |
| 2020 | 24.02 Billion KRW | -80.52% |
| 2019 | 123.33 Billion KRW | 5597.43% |
| 2018 | -2.24 Billion KRW | -162.82% |
| 2017 | 3.57 Billion KRW | -67.75% |
| 2016 | 11.07 Billion KRW | -56.95% |
| 2015 | 25.72 Billion KRW | -0.53% |
| 2014 | 25.86 Billion KRW | 61.04% |
| 2013 | 16.05 Billion KRW | 13.67% |
| 2012 | 14.12 Billion KRW | 38.06% |
| 2011 | 10.23 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 122.09 Billion KRW | 26.73% |
| 2024 Q1 | 98.83 Billion KRW | -9.7% |
| 2023 Q1 | 56.84 Billion KRW | 8.89% |
| 2023 Q3 | 83.54 Billion KRW | 23.51% |
| 2023 Q2 | 67.63 Billion KRW | 18.99% |
| 2023 FY | 308.37 Billion KRW | 47.96% |
| 2023 Q4 | 109.45 Billion KRW | 31.02% |
| 2022 FY | 208.41 Billion KRW | -47.41% |
| 2022 Q4 | 52.2 Billion KRW | -30.94% |
| 2022 Q3 | 75.59 Billion KRW | 66.23% |
| 2022 Q2 | 45.47 Billion KRW | 29.44% |
| 2022 Q1 | 35.13 Billion KRW | -83.62% |
| 2021 FY | 396.3 Billion KRW | 1549.57% |
| 2021 Q4 | 214.55 Billion KRW | 887.3% |
| 2021 Q2 | 21.88 Billion KRW | -84.16% |
| 2021 Q3 | 21.73 Billion KRW | -0.7% |
| 2021 Q1 | 138.14 Billion KRW | 782.58% |
| 2020 FY | 24.02 Billion KRW | -80.52% |
| 2020 Q4 | 15.65 Billion KRW | 335.83% |
| 2020 Q2 | 1.25 Billion KRW | -64.4% |
| 2020 Q1 | 3.52 Billion KRW | 1556.4% |
| 2020 Q3 | 3.59 Billion KRW | 186.11% |
| 2019 Q4 | -242.12 Million KRW | -396.5% |
| 2019 FY | 123.33 Billion KRW | 5597.43% |
| 2019 Q3 | 81.65 Million KRW | -98.73% |
| 2019 Q2 | 6.43 Billion KRW | -94.5% |
| 2019 Q1 | 117.06 Billion KRW | 0.0% |
| 2018 FY | -2.24 Billion KRW | -162.82% |
| 2017 FY | 3.57 Billion KRW | -67.75% |
| 2016 FY | 11.07 Billion KRW | -56.95% |
| 2015 FY | 25.72 Billion KRW | -0.53% |
| 2014 FY | 25.86 Billion KRW | 61.04% |
| 2013 FY | 16.05 Billion KRW | 13.67% |
| 2012 FY | 14.12 Billion KRW | 38.06% |
| 2011 FY | 10.23 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ORIENT BIO Inc. | 9.58 Billion KRW | -3117.461% |
| Green Cross Holdings Corporation | 603.58 Billion KRW | 48.909% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | 32.77% |
| Pharmicell Co., Ltd. | 14.95 Billion KRW | -1961.99% |
| Green Cross Corporation | 458.68 Billion KRW | 32.77% |
| GeneOne Life Science, Inc. | -14.98 Billion KRW | 2157.983% |
| Celltrion, Inc. | 1010.9 Billion KRW | 69.495% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 82.894% |
| SK bioscience Co.,Ltd. | 142.24 Billion KRW | -116.794% |
| Prestige BioPharma Limited | 689.07 Million KRW | -44651.944% |